{"id":569149,"date":"2026-02-05T23:12:18","date_gmt":"2026-02-05T23:12:18","guid":{"rendered":"https:\/\/www.europesays.com\/us\/569149\/"},"modified":"2026-02-05T23:12:18","modified_gmt":"2026-02-05T23:12:18","slug":"fort-worths-rainwater-charitable-foundation-announces-2026-rainwater-prize-winners-dallas-innovates","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/569149\/","title":{"rendered":"Fort Worth’s Rainwater Charitable Foundation Announces 2026 Rainwater Prize Winners \u00bb Dallas Innovates"},"content":{"rendered":"

\"\"<\/p>\n

Dr. Melissa Murray with a digitally printed \u201cbrain art\u201d of her late grandmother [Photo Courtesy Dr. Melissa Murray]<\/p>\n

The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative research to empower field-advancing programs, resources, and breakthrough discoveries for primary tauopathies, has announced the recipients of its 2026 Rainwater Prize.<\/strong><\/p>\n

The Rainwater Prize honors scientific contributions to the field of neurodegenerative research that target diseases associated with the accumulation of tau protein in the brain, with the goal of translating discoveries into meaningful therapeutic and diagnostic innovations.<\/p>\n

\u201cThis year\u2019s Rainwater Prize recipients are changing how the field understands and can ultimately treat tau-associated neurodegenerative diseases,\u201d RCF President Jeremy Smith said in a statement. \u201cTheir work advances insight into tau biology and brings us closer to the day when patients and families affected by PSP, CBD, and related disorders have real therapeutic options.\u201d<\/p>\n

Award winners<\/p>\n

Dennis W. Dickson, M.D.,<\/strong> Professor of Laboratory Medicine and Pathology, Mayo Clinic Florida; and Melissa E. Murray, Ph.D.,<\/strong> Professor of Neuroscience, Mayo Clinic Florida, will be co-awarded the Outstanding Innovation in Neurodegenerative Research Prize of $400,000.<\/p>\n

Marc Aurel Busche, M.D., Ph.D.,<\/strong> Professor of Dementia and Neurodegenerative Diseases, University of Basel & Programme Leader, UK Dementia Research Institute at University College London, will be awarded the Rainwater Prize for Innovative Early-Career Scientist of $200,000.<\/p>\n

The awardees will be honored for their achievements at the 2026 Tau Global Conference\u00a0in Washington, D.C., on May 14-15.<\/p>\n

Primary tauopathies include devastating disorders such as progressive supranuclear palsy and corticobasal degeneration, for which there are currently no disease-modifying treatments.<\/p>\n

Dickson and Murray will be recognized for their collective efforts yielding transformational insights into the neuropathologic patterns and molecular mechanisms underlying PSP, CBD, and other neurodegenerative diseases. Busche will be honored for discovering the role that soluble oligomeric tau species plays in the dysfunction of neurons and its translational promise for primary tauopathies.<\/p>\n

Outstanding Innovation in Neurodegenerative Research<\/p>\n

Individually and together, Dickson\u2019s and Murray\u2019s achievements have significantly impacted the field of neurodegenerative disease research, RCF said. Together, they direct the world\u2019s largest brain banks focused on tauopathies, collecting over 11,000 brain samples that support the pursuit of personalized therapeutic strategies. <\/p>\n

Dickson\u2019s expertise in neuropathologic diagnostics, including discoveries of mutations associated with frontotemporal dementia and parkinsonism, as well as accurate diagnostic criteria for CBD,\u00a0have helped reshape understanding of tau-related diseases. <\/p>\n

Murray\u2019s application of digital pathology and cutting-edge imaging through her Translational Neuropathology Lab has pioneered advancements in Alzheimer\u2019s disease and tauopathy research through better understanding of neuroimaging and plasma biomarkers. <\/p>\n

Their complementary approaches point to distinct neuropathologic tau distribution patterns, allowing for a more accurate diagnosis, precise assessment of disease severity and brain health, and earlier detection of disease progression in primary tauopathies.<\/p>\n

\u201cI\u2019m thrilled to receive this award for our comprehensive neuropathology and biomarker efforts in the field of neurodegenerative disease alongside Dr. Dickson,\u201d Murray said in a statement. \u201cAs many tau-driven disorders such as PSP, FTD, and CBD remain understudied, the RCF\u2019s commitment to initiatives like the Rainwater Prize is essential in accelerating future therapeutic innovations where there are critical gaps.\u201d<\/p>\n

\u201cReceiving this prestigious prize in collaboration with Dr. Murray is both meaningful and motivating,\u201d Dickson said. \u201cWe are eager to utilize these funds in hopes of advancing efforts to slow and ultimately stop the progression of tau-related diseases.\u201d<\/p>\n

Rainwater Prize for Innovative Early-Career Scientist<\/p>\n

Through his findings, Busche has made meaningful contributions to advancing understanding of tauopathies through innovative in vivo methodologies. He and his lab identified soluble, high-molecular-weight tau as a primary determinant of neuronal dysfunction preceding neurodegeneration, a window in which future targeted interventions could potentially transform the management of primary tauopathies. This discovery suggests that symptoms come not only from irreversible neuronal loss but also from potentially reversible neuronal dysfunction driven by HMW tau.<\/p>\n

\u201cNeurodegenerative disease research is moving rapidly, as we identify more diagnostic markers and shed new light on the biological drivers of these diseases,\u201d said Dr. Busche. \u201cIt is an honor to be recognized by the RCF, and my lab and I look forward to establishing an open data platform linking different tau species characteristics with their effects on brain activity to accelerate collective progress toward meaningful treatments.\u201d<\/p>\n

The Rainwater Charitable Foundation was created in the early 1990s by Richard E. Rainwater, the late private equity investor and philanthropist. When Rainwater was diagnosed with a rare neurodegenerative disease and primary tauopathy called Progressive Supranuclear Palsy, the RCF expanded its mission to accelerate the development of new diagnostics and treatments for tau-related neurodegenerative disorders.\u00a0<\/p>\n

Don\u2019t miss what\u2019s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/p>\n

Track Dallas-Fort Worth\u2019s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n

\u00a0<\/p>\n

\tR E A D\u00a0\u00a0 N E X T\t<\/p>\n